Teriparatide

Teriparatide is a manufactured version of the first 34 amino acids of human parathyroid hormone (PTH), the part of the hormone that binds the PTH1 receptor ¹. Unlike osteoporosis drugs that mainly slow bone breakdown, teriparatide is anabolic: short daily pulses of PTH1R activation increase the number and activity of bone-forming cells (osteoblasts), which builds bone mass, improves microarchitecture, and raises bone strength ¹.

Approved in the US in 2002 and the EU in 2003, it is indicated for postmenopausal women at high fracture risk, men with primary or hypogonadal osteoporosis, and glucocorticoid-induced osteoporosis ¹. It was the first anabolic osteoporosis therapy ¹.

Research beyond the label covers delayed fracture healing and nonunion, spinal fusion, medication-related osteonecrosis of the jaw (MRONJ), hypoparathyroidism, and several special populations ¹⁵. Evidence for the approved osteoporosis indication comes from large randomized trials; many off-label uses rest on smaller observational studies ¹.

Bone formation markers peak at 6 to 12 months, so a complete course is typically 18 to 24 months, followed by an antiresorptive medicine to lock in gains ¹. Biosimilars followed the reference product: Terrosa was approved in the EU in 2017, and US biosimilars reached the market after exclusivity ended in October 2019 ⁴⁵. A once-weekly 56.5 mcg (product label) formulation was validated in Japan's TOWER trial ⁴¹.

Daily pulses make the difference. Teriparatide is the active 1-34 fragment of parathyroid hormone (PTH), the portion that binds the PTH1 receptor ¹. With continuous exposure, PTH drives bone breakdown; with a brief pulse, it drives bone formation. This intermittency principle appears across animal and human dosing studies ⁴¹.

Where the signal lands

The receptor sits on osteoblasts, the cells that build bone, and on osteocytes, mature bone cells embedded in mineral ³⁷. Activation raises cyclic AMP and calcium inside the cell, then engages protein kinase A (PKA) and salt-inducible kinases, which control the CRTC/CREB transcription machinery. That machinery shifts expression of genes such as RANKL, c-Fos, and sclerostin ⁴⁹. Teriparatide, abaloparatide, and longer-acting PTH analogs engage these same intracellular cascades; the differences seen in the clinic are thought to come mainly from how long each drug stays in the body, not from a distinct signaling pathway ⁵⁰.

Studies that delete PTH1R only in osteocyte-lineage cells show that the receptor on osteocytes is essential for gains in bone mass and bone strength, even though some remodeling signals continue ³⁷. PTH pulses also lower sclerostin, releasing the Wnt pathway from inhibition, and rapidly induce MCP1, a chemokine required for the anabolic effect in animals ⁵⁴. At the progenitor level, it raises Osterix and Runx2, transcription factors that steer immature cells toward becoming osteoblasts ⁵⁵. In cartilage, PTH1R signals can push mature hypertrophic chondrocytes back toward a proliferating, prehypertrophic state, which may matter at bone-cartilage repair interfaces ⁵⁶.

Why the response peaks

The bone-building response is not indefinite. Formation markers such as P1NP and osteocalcin rise within weeks, peak around 6 to 12 months, and then decline even with continued dosing. Proposed limiting factors include depletion of osteoblast precursors and counter-regulation of Wnt inhibitors ³⁴. An absent early marker response at 3 months predicts a smaller spine BMD gain ³⁵. Genetic background and sex also influence who responds and where; in animal models, hip non-response is more common than spine non-response, mirroring human observation ³⁶.

After a 20 mcg subcutaneous dose, peak drug levels occur around 25 to 36 minutes, the elimination half-life is about 1 hour, and measurable exposure is mostly finished by 4 hours. Serum calcium rises modestly and temporarily, peaking about 4.25 hours after the dose and returning to baseline by 16 to 24 hours ².

Bone density and fracture outcomes

In the pivotal 1,637-woman randomized trial, 18 months of 20 mcg daily subcutaneous teriparatide reduced new vertebral fractures by 65% and nonvertebral fractures by 35%. Lumbar spine BMD rose 9.7% and total hip BMD rose 2.6% ¹. In glucocorticoid-induced osteoporosis, a network meta-analysis found the largest lumbar spine BMD gains among anti-osteoporotic drugs, surpassing alendronate, risedronate, denosumab, and zoledronate, and comparable to romosozumab ⁹. Hip fracture evidence for teriparatide is more indirect; guidance positions it for very-high-risk patients while bisphosphonates, denosumab, and romosozumab carry the strongest hip fracture data ¹⁴.

In real-world comparative data, romosozumab showed lower vertebral fracture rates than teriparatide in patients with chronic kidney disease (HR 0.64) and lower any osteoporotic fracture risk in a large matched cohort (HR 0.68) ¹⁰. Teriparatide's cardiovascular reporting profile is covered in the safety section.

Persistence is a practical weakness. Twelve-month completion was 52.9% for daily teriparatide versus higher rates for monthly or semiannual alternatives ¹². Claims data show only about 30% of patients complete a course of at least 18 months, and only 25% start consolidation with an antiresorptive within 3 months ¹³.

Prior bisphosphonate treatment modestly blunts lumbar spine BMD gains by about 2.2 percentage points, with less effect at the hip ⁸. When transitioning off denosumab, continuing denosumab while adding teriparatide produced larger spine BMD gains than a sequential switch (9.4% versus 5.6%) and avoided resorption rebound ⁷.

Fracture healing

In a prospective 48-patient study of delayed long-bone union, 20 mcg daily for 3 months produced radiologic union in 81.2% at 12 weeks, and pain scores fell from 7.8 to 2.1 ²¹. An exploratory cohort with aseptic tibial shaft nonunion reported shorter time to healing with teriparatide after reamed nailing (87.5 versus 99.7 days) ²². Vertebral compression fractures healed faster than with alendronate (6-month union 89% versus 68%) ²³. A randomized trial did not find improved healing of proximal humerus fractures after 4 weeks of treatment ²⁴. Atypical femoral fractures in patients with long-term bisphosphonate use healed on teriparatide in a case report; switching to denosumab mid-healing caused symptom recurrence ³³.

Other studied uses

For medication-related osteonecrosis of the jaw (MRONJ), a systematic review reported complete healing in 163 of 201 compiled patients, most often with daily dosing ²⁶. A meta-analysis estimated a healing hazard ratio of 5.35 versus conventional care, though the underlying studies are heterogeneous and observational ²⁵.

In children with hypoparathyroidism, teriparatide maintained serum calcium and lowered phosphate in a meta-analysis of 94 patients, though conventional therapy remains first-line ²⁷. In adults with refractory hypoparathyroidism, once-daily 20 mcg raised calcium at 3 months but did not always sustain it at 6 months; symptom relief was consistent ²⁹. Small reports describe rescue with twice-daily dosing for hungry-bone hypocalcemia and encouraging outcomes in a toddler with an activating calcium-sensing receptor mutation ²⁸.

In solid-organ transplant recipients, a 39-patient retrospective cohort reported lumbar spine +11%, femoral neck +8%, and total hip +11% over a median 22.3 months, with no graft rejection ³¹. A multi-society position statement supports teriparatide/abaloparatide or romosozumab as preferred pharmacotherapy for pregnancy- and lactation-associated osteoporosis when used with contraception ³². In osteogenesis imperfecta, a 349-patient randomized trial found no reduction in fractures despite BMD gains (36.9% versus 36.4% with standard care) ¹⁹. For bone stress injuries in otherwise healthy athletes, routine use is not supported ²⁰. In a 7-patient pilot, teriparatide improved lumbar spine BMD in hemodialysis-associated adynamic bone disease ⁴⁰.

In mice with post-traumatic knee osteoarthritis, teriparatide regenerated a thicker cartilage layer and reduced markers of cartilage breakdown, but this is preclinical proof-of-concept ⁴².

Teriparatide dosing is fixed rather than weight-based. The approved osteoporosis protocol uses 20 mcg subcutaneously once daily, typically for 18 to 24 months, then consolidates with an antiresorptive ¹. A 40 mcg daily dose has also been studied in some trials ⁵⁸. Japan validated a once-weekly 56.5 mcg (product label) formulation that reduced new vertebral fractures in the TOWER trial ⁴¹.

Representative research protocols include:

Indication	Regimen studied	Duration	Evidence
Osteoporosis at high fracture risk	20 mcg SC once daily	18 to 24 months, then antiresorptive	Randomized controlled trial 1
Osteoporosis with hormone therapy	40 mcg SC daily plus HRT	About 14 months	Randomized controlled trial 58
Delayed union or nonunion	20 mcg SC daily with calcium and vitamin D	3 to 4 months	Prospective cohort and case reports 21
Perioperative spine fusion	20 mcg SC daily	3 months before and 3 months after surgery	Observational and meta-analyses 15
MRONJ adjunct	20 mcg SC daily	3 to 6 months (community protocol)	Systematic reviews 25
Refractory hypoparathyroidism	20 mcg SC once to twice daily, titrated	Weeks to months	Case series and Delphi consensus 29
Hemodialysis adynamic bone disease	20 mcg SC daily; twice-weekly dosing under study	6 months in pilot	Pilot and trial protocol 40

A subcutaneous dose produces peak drug levels around 30 minutes, a transient calcium rise peaking about 4.25 hours later, and returns to baseline by 16 to 24 hours ². The pulse must stay short-lived; daily pulsing produces stronger bone formation than weekly pulsing in animal models, and continuous exposure would shift the response toward breakdown ⁴¹. Time of day is not established as a response modifier; consistency matters more than clock hour. Trials co-administered 1,000 mg calcium and 400 to 1,200 IU vitamin D daily ⁵⁸.

Lifetime exposure is capped at 24 months, and there is no support for repeat alternating courses. The critical sequence is not cycling back to teriparatide but following it promptly with an antiresorptive. Without that, about 2 to 3% of lumbar spine BMD is lost within 2.5 years ¹. In practice, only 25% of patients consolidate within 3 months ¹³. When withdrawing denosumab, combination initiation with teriparatide outperformed a sequential switch on spine BMD ⁷.

Human dosing is fixed at 20 mcg, which implies roughly 0.20 to 0.36 mcg/kg daily across ordinary adult weights. Animal studies use higher weight-scaled doses because of species pharmacokinetic differences; for example, nonhuman primate studies used 1 to 5 mcg/kg daily ⁶⁷. These animal doses should not be converted into human regimens.

Clinical teriparatide products are ready-to-use injection solutions delivering a fixed dose; the reference product is supplied as a multi-dose injector ¹. For research-grade lyophilized vials, standard preparation uses bacteriostatic water containing 0.9% benzyl alcohol. Sterile saline is an alternative diluent when benzyl alcohol is not tolerated.

Add the diluent slowly down the vial wall and swirl gently. Do not shake or vortex the vial. The interactive calculator below handles the dilution and dose-volume math.

Storage and stability

Lyophilized powder is stored frozen at -20°C for long-term storage; unopened vials may be kept at 2 to 8°C for months. Protect powder from light and moisture. Solid-state PTH(1-34) stability has been characterized under controlled conditions ⁹⁵.

After reconstitution, keep the vial refrigerated at 2 to 8°C and do not freeze it. Reconstituted lyophilized teriparatide has been formally characterized for stability ⁸³. Standard practice is to hold reconstituted material for no more than 28 days under sterile refrigeration and discard earlier if it becomes cloudy or shows particulates.

Proteolysis is the primary degradation pathway. Mass spectrometry identifies PTH 1-33 as a degradation fragment, and immunoassays can overestimate late intact concentrations, so stability monitoring should use intact-molecule assays ⁵¹. Source-specific impurities, such as amino acid deletions in synthetic material, affect vial purity at reconstitution rather than storage stability ⁴⁴.

Drug interactions

• Denosumab: Combining teriparatide with continued denosumab produced greater gains in vertebral marrow quality, lumbar spine BMD (+9.4% vs +5.6%), and trabecular bone score than sequentially switching, while keeping bone resorption suppressed ⁷. Abrupt denosumab withdrawal carries rebound fracture risk; data suggest teriparatide plus zoledronate may help when denosumab must be stopped ⁸⁷.
• Bisphosphonates: Prior bisphosphonate exposure attenuates lumbar spine BMD gains by about 2.21 percentage points without clear effect on hip BMD ⁸. Concurrent alendronate does not add hip benefit and may blunt the response ⁸⁸.
• Hormone replacement therapy: Additive. In a randomized trial, 40 mcg daily plus HRT gave about +14% spine BMD versus +3% with HRT alone, with additive hip gains but more nausea and leg cramps ⁵⁸.
• Calcitriol and calcium: In hypoparathyroidism and calcium-sensing receptor defects, adequate vitamin D and calcium can maximize effect and allow dose reductions ⁷⁶. Add calcium cautiously because teriparatide transiently raises serum calcium and is the most commonly reported drug in FAERS hypercalcemia reports ⁵.
• Warfarin: Warfarin blocks vitamin K recycling, and warfarin plus glucocorticoids plus teriparatide has been reported with nonuremic calciphylaxis ⁸⁵. Vitamin K-dependent osteocalcin carboxylation may support repair efficacy ⁸⁹.
• Glucocorticoids: Teriparatide produced the largest lumbar spine BMD gains among comparators in glucocorticoid-induced osteoporosis ⁹. The combination with warfarin plus steroids is a cautionary case ⁸⁵.
• Thiazide diuretics: They reduce urinary calcium and could theoretically add to transient hypercalcemia; in one calcium-sensing receptor disorder case they were used adjunctively to control hypercalciuria ⁷⁶.
• Digitalis glycosides: Theoretical risk from transient hypercalcemia lowering the arrhythmia threshold ².
• Romosozumab: This is a sequencing choice, not a co-use. Overlap adds no value, and comparative data inform agent selection ⁶.
• Lithium, loop diuretics, and GLP-1 receptor agonists: No teriparatide-specific data; interactions are theoretical or based on calcium physiology.

Supplement interactions

• Calcium and vitamin D: Required companions in osteoporosis studies, but do not escalate calcium aggressively because it compounds hypercalcemia risk ⁵.
• Vitamin K: Maintain vitamin K status; warfarin antagonizes vitamin K-dependent osteocalcin carboxylation ⁸⁹.
• Strontium: Co-treatment potentiated teriparatide in ovariectomized rats, but no human data exist ⁶⁶.
• Pyrroloquinoline quinone (PQQ): Animal research shows synergy through the Nrf2-Pth1r axis, but this is experimental ⁹¹.
• Fish oil and omega-3: No documented interaction; the anticoagulant concern applies specifically to vitamin K antagonists ⁸⁵.

The strongest evidence-backed combination is teriparatide with continued denosumab, which outperformed a sequential switch on vertebral marrow quality, spine BMD, and trabecular bone score ⁷.

PTH1R agonists should not be stacked. Teriparatide, abaloparatide, and palopegteriparatide all signal through the PTH type-1 receptor ⁵⁰. Palopegteriparatide is a PTH(1-34) prodrug used for hypoparathyroidism replacement ⁴⁸. Concurrent use duplicates the pathway and adds hypercalcemia risk without anabolic synergy.

Other combinations studied:

• BMP-2: In rat spinal fusion, intermittent teriparatide accelerated modeling and remodeling of BMP-2-induced fusion bone and improved microstructural indices ⁹⁴.
• Strontium: In ovariectomized rats, strontium plus PTH improved trabecular thickness, tissue-level bone density, and maximum force versus PTH alone ⁶⁶.
• PQQ: In aged mice, PQQ potentiated PTH anabolic responses via the Nrf2-Pth1r axis ⁹¹.
• Whole-body vibration: In a human randomized trial, adding vibration three times weekly produced an extra +2.95% lumbar spine BMD beyond teriparatide alone at 12 months ⁷⁷.
• Hormone replacement therapy: Additive bone density gains are documented ⁵⁸.

For research peptides such as BPC-157, TB-500, and growth hormone secretagogues, no direct evidence for co-use with teriparatide appears in the reviewed documents. If such combinations are studied, serum calcium and bone-turnover markers are the key safety parameters because teriparatide's calcium effects dominate the risk profile.

Teriparatide was approved by the FDA in 2002 as the first anabolic osteoporosis therapy, and the EU followed in 2003 ¹. It is prescription-only, with no DEA scheduling. Approved indications cover postmenopausal women at high fracture risk, men with primary or hypogonadal osteoporosis, and glucocorticoid-induced osteoporosis ¹.

The label is shaped by a rat toxicology signal: high-dose, near-lifetime exposure produced osteosarcomas in animals, while no case emerged among roughly 2,800 trial patients ¹. FDA labeling caps cumulative lifetime exposure at 24 months. A FAERS analysis through early 2025 found 29 osteosarcoma reports with elevated reporting odds versus all drugs (ROR 15.31) but no signal against the romosozumab comparator, and causality remains unestablished ⁴. FAERS also ranks teriparatide as the most frequently reported drug in drug-induced hypercalcemia cases ⁵.

Biosimilars and alternatives: Terrosa was approved in the EU in 2017 ⁴⁵. After US reference exclusivity expired in October 2019, biosimilars reached the market through the 505(b)(2) pathway ⁴⁶. Japan has a once-weekly 56.5 mcg (product label) formulation validated in the TOWER trial ⁴¹. Palopegteriparatide, a PTH(1-34) prodrug, is FDA-approved for adult hypoparathyroidism, while teriparatide itself remains off-label for that indication ⁴⁸.

Sports and WADA: The reviewed regulatory document states that teriparatide and PTH analogs are not named in any WADA Prohibited List category, are excluded from S2 peptide hormones/growth factors and S1 anabolic agents, and because teriparatide is an approved human therapeutic, S0 does not apply. Unapproved PTH-receptor constructs without authorization in any jurisdiction would fall under S0.

Jurisdiction	Status
US FDA	Approved 2002; biosimilar via 505(b)(2) October 2019 1
EU EMA/EC	Forsteo authorized 2003; Terrosa biosimilar approved January 2017 1
WADA	Not prohibited in any category

Common effects

In the pivotal trial, dizziness and leg cramps were significantly more common than placebo; nausea and headache also occurred ¹. A real-world biosimilar comparison reported adverse-event rates around 7.4% to 9.9%, mostly constipation, nausea, and fatigue ⁴⁶. Injection-site reactions are common with daily subcutaneous use.

The calcium signal

Each injection produces a transient serum calcium rise, about +0.4 mg/dL at roughly 4.25 hours, resolving by 16 to 24 hours ². Persistent predose hypercalcemia is uncommon at 20 mcg: dose reduction occurred in 3% and discontinuation in 0.2% in the pivotal trial ¹. Teriparatide is the most frequently reported drug in FAERS hypercalcemia reports (2,539 cases), so calcium monitoring matters ⁵.

Rare and theoretical risks

• Osteosarcoma: FAERS shows elevated reporting versus all drugs (ROR 15.31) but not versus romosozumab, and clinical trials have not shown cases; causality remains unresolved ⁴.
• Cutaneous vascular calcification: Case reports occurred in patients also on warfarin and glucocorticoids; lesions improved after stopping teriparatide ⁸⁵.
• Male reproductive toxicity: Rats given 10 mcg/kg daily for 60 days showed seminiferous tubule changes; no human data exist ³⁸.
• Cardiovascular profile: Teriparatide and abaloparatide show among the lowest MACE reporting odds of osteoporosis therapies ⁶.

Contraindications and cautions

Absolute contraindications from the reviewed documents include preexisting hypercalcemia, Paget's disease of bone, unexplained alkaline phosphatase elevation, prior radiation to the skeleton, active or metastatic bone malignancy, and hypersensitivity to teriparatide or its excipients.

Relative cautions include history of malignancy, kidney stones or hypercalciuria, severe renal impairment or dialysis, warfarin plus glucocorticoid use, pregnancy, and breastfeeding. Use in children is off-label; conventional therapy remains first-line for hypoparathyroidism ²⁷. Pediatric osteoporosis use is not established because the osteogenesis imperfecta trial showed no fracture reduction despite BMD gains ¹⁹.

Monitoring

Before starting: corrected serum calcium, phosphate, 25-hydroxy vitamin D, creatinine/eGFR, 24-hour urine calcium, and uric acid. During treatment: predose calcium at about 1 month and after dose changes, then every 3 to 6 months; P1NP at 3 months to detect non-response ³⁵; 24-hour urine calcium if hypercalcemia or stone history; eGFR at 3 to 6 months in at-risk patients such as transplant or kidney disease ³¹. After stopping: start antiresorptive consolidation within 3 months, which only about 25% of patients receive in practice ¹³.